GlycoNex Of Taiwan, Otsuka Pharma Open Colorectal Cancer Drug Trials
This article was originally published in PharmAsia News
Taiwan's GlycoNex said it has plans to develop a drug in at least once every three years to follow on its recent beginning of clinical trials in Japan of its GNX-8, an antibody for treating colorectal cancer.
You may also be interested in...
Once a pariah because of its price-gouging, the new approval represents a change of tack from Horizon.
Erik Hansson remains deputy head of devices in a move to the European Commission’s DG Sante from DG Grow. He now answers to a newly appointed devices head who shares a common educational background but whose recent pharmaceutical role may unsettle the devices industry.
Steve Niedelman of the law firm King & Spalding gave manufacturers a few words of advice when prepping their so-called front rooms, where US FDA investigators do the majority of their work during facility inspections. See what he said here.